Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has expanded its clinical team by hiring two Clinical Research Associates, Bhavya Bajantri and Sonia Keshwani.
The Toronto-based pharmaceutical company is researching and developing light and/or radiation-activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria, and viruses.
It said the two Clinical Research Associates will work with its clinical study sites to complete its Phase 2 registration bladder cancer trial of its photodynamic therapy Rudivar, known as Study II.
This will include launching new clinical study sites in Canada and the United States, enrolling all patients into the clinical study during 2024, and reviewing and analyzing the existing clinical data to ensure accuracy.
They will also secure review ethics board approval and patient consent to obtain patient clinical data up to three years from the date of the primary Study Procedure and provide training and support on central pathology analysis of urine cytology and bladder biopsy pathology samples.
"The company looks forward to working with Bhavya and Sonia in their new roles and their participation in the successful and timely completion of Study II,” Theralase CEO Roger DuMoulin-White commented.
“The ultimate goal of our ongoing Phase 2 clinical study is to commercialize Ruvidar in Canada, the United States and internationally to provide a safe and effective treatment for as many patients, as possible, who are afflicted with this deadly disease."